

An open, randomised phase I/II dose escalation study evaluating the safety and tolerability, pharmacokinetics, antigenicity and efficacy of Iodine-131-Kab201 when given intra-arterially or intravenously in patients with surgically unresectable pancreatic ductal adenocarcinoma

Submission date 12/09/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 19/10/2005	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 10/05/2012	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

<http://cancerhelp.cancerresearchuk.org/trials/monoclonal-antibody-and-iodine-treatment-for-advanced-cancer-of-the-pancreas>

Contact information

Type(s)

Scientific

Contact name

Prof John Neoptolemos

Contact details

Royal Liverpool University Hospital
Prescot Street
Liverpool
United Kingdom
L7 8XP
+44 (0)151 706 4175
j.p.neoptolemos@liverpool.ac.uk

Additional identifiers

Protocol serial number

Study information

Scientific Title

Acronym

KaBI

Study objectives

To assess the safety, tolerability and efficacy of targeted radiotherapy to pancreas using anti-carcinoembryonic antigen (CEA) monoclonal antibody labelled with Iodine-131.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Pancreatic adenocarcinoma unsuitable for curative resection.

Interventions

Iodine-131-Kab201 given intra-arterially or intravenously

Intervention Type

Other

Phase

Phase I/II

Primary outcome(s)

To evaluate the safety, tolerability and maximum tolerated dose of Iodine-131-Kab201 when administered either intra-arterially or intravenously in patients with unresectable pancreatic cancer.

Key secondary outcome(s)

To assess the pharmacokinetics, antigenicity and evaluate efficacy of Iodine-131-Kab201 when administered either intra-arterially or intravenously in patients with unresectable pancreatic cancer.

Completion date

31/10/2005

Eligibility

Key inclusion criteria

1. Male or female; aged 18 or over
2. Histologically proven diagnosis of ductal adenocarcinoma in the head of the pancreas
3. Advanced pancreatic ductal adenocarcinoma involving the head of the pancreas and thus unsuitable for potentially curative resection
4. At least one confirmed and measurable tumour site on computed tomography (CT) documented within 4 weeks of randomisation
5. Karnofsky Score of 70 or more
6. Life expectancy of greater than or equal to 3 months
7. Women of childbearing potential must have a negative pregnancy test at the time of screening and must be willing to practice appropriate contraceptive methods for the duration of the study. Men with partners of childbearing potential must also be willing to practice appropriate barrier contraceptive methods for the duration of the study.
8. Written informed consent to participate in the study

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Leucopenia and/or granulocytopenia
2. Thrombocytopenia
3. Significant and worsening hepatic impairment (aspartate aminotransferase/alanine aminotransferase [AST/ALT] >3 x the upper limit of normal [ULN]; bilirubin >5 x ULN) in the absence of obstructive jaundice. Liver function tests must be stable or improving at time of investigational drug administration.
4. Significant renal impairment (serum creatinine >ULN)
5. Known immunological reactions to previously administered antibodies, proteins or iodine
6. Pregnant or lactating women
7. Radiotherapy or chemotherapy within the preceding 1 month at the scheduled time of dosimetric dosing (preceding 6 weeks for nitrosoureas)
8. Previous external beam radiotherapy to maximal tolerable levels to any critical organ (3000 cGy for liver, 2000 cGy for lungs/kidneys)
9. Treatment with any other clinical trial medication within the 3 months prior to dosimetric

dosing

10. Presence of concomitant condition or circumstances which, in the opinion of the investigator, would render the patient unsuitable for the study, such as ongoing alcohol or drug abuse or being unable to tolerate any of the study procedures (e.g. unable to lie flat for nuclear imaging scans)

Date of first enrolment

01/09/2002

Date of final enrolment

31/10/2005

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Royal Liverpool University Hospital

Liverpool

United Kingdom

L7 8XP

Sponsor information

Organisation

Xenova Ltd (UK)

Funder(s)

Funder type

Industry

Funder Name

Xenova Ltd

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results:	21/07/2006		Yes	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes